Short-term pioglitazone treatment prevents free fatty acid-induced hepatic insulin resistance in normal rats: Possible role of the resistin and adiponectin

Biochemical and Biophysical Research Communications

Volumn 339, Issue 4, 2006, Pages 1190-1196

  Yang, Gangyi ^a   Li, Ling ^a   Tang, Yi ^a   Boden, Guenther ^b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adiponectin; Free fatty acids; Insulin resistance; Pioglitazone; Resistin

Indexed keywords

ADIPONECTIN; FATTY ACID; INSULIN; LIPID; PIOGLITAZONE; RESISTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOT HYBRIDIZATION; HORMONE ACTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER FUNCTION; MALE; MUSCLE TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; TISSUE LEVEL;

ADIPONECTIN; ANIMALS; DRUG INTERACTIONS; FATTY ACIDS, NONESTERIFIED; HEPARIN; INSULIN; INSULIN RESISTANCE; MALE; RATS; RATS, SPRAGUE-DAWLEY; RESISTIN; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

ANIMALIA;

EID: 29044437122     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.11.143     Document Type: Article

References (30)

1. A.R. Saltiel, and J.O. Olefsky Thiazolidinediones in the treatment of insulin resistance and type II diabetes Diabetes 45 1996 1661 1669
2. J.M. Lehman, L.B. Moor, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, and S.A. Kliewwr An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ) J. Biol. Chem. 270 1995 12953 12956
3. T.M. Wilson, J.E. Cobb, D.J. Cowan, R.W. Wiethe, I.D. Correa, S.R. Prakash, K.D. Beck, L.B. Moore, S.A. Kliewer, and J.M. Lehmann The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones J. Med. Chem. 39 1996 665 668
4. G. Boden, P. Cheung, M. Mozzoli, and S.K. Fried Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes Metabolism 52 2003 753 759
5. M.N. Ghazzi, J.E. Perez, J.H. Driscoll, S.M. Huang, B.W. Faja, and R.W. Whitcomb Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group Diabetes 46 1997 433 439
6. D.G. Maggs, T.A. Buchanan, C.F. Burant, G. Cline, B. Gumbiner, W.A. Hsueh, S. Inzucchi, D. Kelley, J. Nolan, J.M. Olefsky, K.S. Polonsky, D. Silver, T.R. Valiquett, and G.I. Shulman Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus Ann. Intern. Med. 128 1998 176 185
7. E. Chaput, R. Saladin, and M. Silvestre Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight Biochem. Biophys. Res. Commun. 271 2002 445 450
8. G. Boden Role of fatty acids in the pathogenesis of insulin resistance and NIDDM Diabetes 46 1997 3 10
9. E.E. Kershaw, and F.S. Flier Adipose tissue as an endocrine organ J. Clin. Endocrinol. Metab. 89 2004 2548 2556
10. N. Maeda, T.M. Takahashi, T. Funahashi, S. Kihara, H. Nishizawa, K. Kishida, H. Nagaretani, M. Matsuda, R. Komuro, N. Ouchi, and Y. Matsuzawa PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein Diabetes 50 2001 2094 2099
11. T. Yamauchi, J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami, N. Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C. Vinson, M.L. Reitman, H. Kagechika, K. Shudo, M. Yoda, Y. Nakano, K. Tobe, R. Nagai, S. Kimura, M. Tomita, P. Froguel, and T. Kadowaki The fat-derived hormone adiponectin reverses insulin resistance associated with both lipatrophy and obesity Nat. Med. 7 2001 941 946
12. C.M. Steppan, and M.A. Lazar The current biology of resistin J. Intern. Med. 255 2004 439 447
13. C.M. Steppan, S.T. Bailey, S. Bhat, E.J. Brown, R.R. Banerjee, C.M. Wright, H.R. Patel, R.S. Ahima, and M.A. Lazar The hormone resistin links obesity to diabetes Nature 409 2001 307 312
14. J.M. Way, C.Z. Gorgun, Q. Tong, K.T. Uysal, K.K. Brown, W.W. Harrington, W.R. Oliver, T.M. Willson, S.A. Kliwer, and G.S. Hotamisligil Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor γ agonists J. Biol. Chem. 276 2001 25651 25653
15. M.W. Rajala, S. Obici, P.E. Scherer, and L. Rossetti Adipose-derived resistin and gut-derived resistin-like molecule-βselectively impair insulin action on glucose production J. Clin. Invest. 111 2003 225 230
16. R.R. Banerjee, S.M. Rangwala, J.S. Shapiro, A.S. Rich, B. Rhoades, Y. Qi, J. Wang, M.W. Rajala, A. Pocai, P.E. Scherer, C.M. Steppan, R.S. Ahima, S. Obici, L. Rossetti, and M.A. Lazar Regulation of fasted blood glucose by resistin Science 303 2004 1195 1198
17. P. Cheung, G. Yang, and G. Boden Milrinone, a selective phosphodiesterase 3 inhibitor, stimulates lipolysis, endogenous glucose production, and insulin secretion Metabolism 52 2003 1496 1500
18. R. Steele, J.S. Wall, and R.C. DeBodo Measurement of size and turnover rate of body glucose pool by the isotope dilution method Am. J. Physiol. 187 1956 15 24
19. J-M. Ye, G. Frangioudakis, M.A. Iglesias, F. Stuart-M, E. Bronwyn, D. Nicholas, C. Gregory-J, and K. Edward Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver Endocrinology 143 2002 4527 4535
20. J. Tonelli, W. Li, P. Kishore, U.B. Pajvani, E. Kwon, C. Weaver, P.E. Scherer, and M. Hawkins Mechanism of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes Diabetes 53 2004 1621 1629
21. A.L. Hevener, D. Reichart, A. Janez, and J. Olefsky Thiazolidinedione treatment prevents free fatty acid-induced resistance in male Wistar rats Diabetes 50 2001 2316 2322
22. J.J. Nolan, B. Ludvik, P. Beerdsen, M. Joyce, and J. Olefsky Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone N. Engl. J. Med. 331 1994 1188 1893
23. T.P. Combs, A.H. Berg, S. Obici, P.E. Scherer, and L. Rossetti Endogenous glucose production is inhibited by the adipose-derived protein Acrp30 J. Clin. Invest. 108 2001 1875 1881
24. H. Satoh, M.T.A. Nguyen, P.D.G. Miles, T. Imamura, I. Usui, and J.M. Olefsky Adenovirus-mediated chronic "hyper-resistinemia" leads to vivo insulin resistance in normal rats J. Clin. Invest. 114 2004 224 231
25. J.M. Ye, N. Dzamko, M.E. Cleasby, B.D. Hegarty, S.M. Furler, G.J. Cooney, and E.W. Kraegen Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevent fatty-acid-induced insulin resistance in the rat: comparison with metformin Diabetologia 47 2004 1306 1313
26. P. Tontonoz, E. Hu, R.A. Graves, A.I. Budavari, and B.M. Spiegelman mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer Genes. Dev. 8 1994 1224 1234
27. Y.T. Kruszynska, R. Mukherjee, L. Jow, S. Dana, J.R. Petemiti, and J.M. Olefsky Skeletal muscle peroxisome proliferator-activated receptor-gamma expression in obesity and non-insulin dependent diabetes mellitus J. Clin. Invest. 101 1998 543 548
28. G. Boden, C. Homko, M. Mozzoli, L.C. Showe, C. Nichols, and P. Cheung Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetes patients Diabetes 54 2005 880 885
29. S.I. Itani, N. BRuderman, F. Schmieder, and G. Boden Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α Diabetes 51 2002 2005 2010
30. G. Boden, P. She, and M. Mozzoli Free fatty acids produce insulin resistance and activate the proinflammatory NFκB pathway in rat liver Diabetes 54 2005 3458 3465